NEW YORK (GenomeWeb News) – Asterand said today that it will validate and characterize antibodies and immunohistochemistry applications for antibody marketer Abcam.

Under the collaborative agreement, Asterand will use its PhaseZero Human Tissue Services platform and its Target Evaluator gene expression database to select antibodies and to identify expression patterns for their use with human tissue.

The resulting data will be incorporated into Abcam’s literature and technical support documentation for each antibody tested and will be sold through its online catalogue.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.